{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:42:14Z","timestamp":1736538134282,"version":"3.32.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2006,9,5]],"date-time":"2006-09-05T00:00:00Z","timestamp":1157414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,10,27]]},"DOI":"10.1007\/s00228-006-0189-9","type":"journal-article","created":{"date-parts":[[2006,9,4]],"date-time":"2006-09-04T15:00:18Z","timestamp":1157382018000},"page":"939-946","source":"Crossref","is-referenced-by-count":4,"title":["Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese"],"prefix":"10.1007","volume":"62","author":[{"given":"T.","family":"Yasumori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,5]]},"reference":[{"key":"189_CR1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","volume":"39","author":"KD Kaufman","year":"1998","unstructured":"Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ (1998) Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39:578\u2013589","journal-title":"J Am Acad Dermatol"},{"key":"189_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/13543784.8.4.403","volume":"8","author":"KD Kaufman","year":"1999","unstructured":"Kaufman KD, Dawber RP (1999) Finasteride, a Type 2 5-alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia. Expert Opin Investig Drugs 8:403\u2013415","journal-title":"Expert Opin Investig Drugs"},{"key":"189_CR3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1046\/j.1365-2133.2000.03780.x","volume":"143","author":"D Neste Van","year":"2000","unstructured":"Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene JJ, Calvieri S, Tosti A, Prens E, Guarrera M, Kanojia P, He W, Kaufman KD (2000) Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 143:804\u2013810","journal-title":"Br J Dermatol"},{"key":"189_CR4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archderm.135.8.989","volume":"135","author":"KD Kaufman","year":"1999","unstructured":"Kaufman KD (1999) Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. Arch Dermatol 135:989\u2013990","journal-title":"Arch Dermatol"},{"key":"189_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1067\/mjd.2002.120537","volume":"46","author":"VH Price","year":"2002","unstructured":"Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD (2002) Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 46:517\u2013523","journal-title":"J Am Acad Dermatol"},{"key":"189_CR6","first-page":"247","volume":"14","author":"M Kawashima","year":"2004","unstructured":"Kawashima M, Hayashi N, Igarashi A, Kitahara H, Maeguchi M, Mizuno A, Murata Y, Nogita T, Toda K, Tsuboi R, Ueki R, Yamada M, Yamazaki M, Matsuda T, Natsumeda Y, Takahashi K, Harada S (2004) Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol 14:247\u2013254","journal-title":"Eur J Dermatol"},{"key":"189_CR7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0753-3322(96)82660-6","volume":"49","author":"P Roylance","year":"1995","unstructured":"Roylance P, Gibelin B, Espie J (1995) Current treatment of BPH. Biomed Pharmacother 49:332\u2013338","journal-title":"Biomed Pharmacother"},{"key":"189_CR8","first-page":"38","volume":"12","author":"Finasteride Male Pattern Hair Loss Study Group","year":"2002","unstructured":"Finasteride Male Pattern Hair Loss Study Group (2002) Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 12:38\u201349","journal-title":"Eur J Dermatol"},{"key":"189_CR9","first-page":"150","volume":"13","author":"DA Whiting","year":"2003","unstructured":"Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, Hustad C, Palmisano J; Male Pattern Hair Loss Study Group (2003) Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol 13:150\u2013160","journal-title":"Eur J Dermatol"},{"key":"189_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2165\/00003088-199630010-00002","volume":"30","author":"JF Steiner","year":"1996","unstructured":"Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30:16\u201327","journal-title":"Clin Pharmacokinet"},{"key":"189_CR11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/j.1552-4604.1996.tb04172.x","volume":"36","author":"EE Samara","year":"1996","unstructured":"Samara EE, Hosmane B, Locke C, Eason C, Cavanaugh J, Granneman GR (1996) Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. J Clin Pharmacol 36:1169\u20131178","journal-title":"J Clin Pharmacol"},{"key":"189_CR12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/009127009803801113","volume":"38","author":"V Vashi","year":"1998","unstructured":"Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K (1998) Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. J Clin Pharmacol 38:1072\u20131076","journal-title":"J Clin Pharmacol"},{"key":"189_CR13","first-page":"1126","volume":"23","author":"SW Huskey","year":"1995","unstructured":"Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH (1995) Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 23:1126\u20131135","journal-title":"Drug Metab Dispos"},{"key":"189_CR14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2125.1985.tb02673.x","volume":"19","author":"M Jurima","year":"1985","unstructured":"Jurima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(4\u2032)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 19:483\u2013487","journal-title":"Br J Clin Pharmacol"},{"key":"189_CR15","first-page":"853","volume":"25","author":"JW Ko","year":"1997","unstructured":"Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853\u2013862","journal-title":"Drug Metab Dispos"},{"key":"189_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2036.1990.tb00476.x","volume":"4","author":"AS Guerreiro","year":"1990","unstructured":"Guerreiro AS, Neves BC, Quina MG (1990) Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists. Aliment Pharmacol Ther 4:309\u2013313","journal-title":"Aliment Pharmacol Ther"},{"key":"189_CR17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2125.1993.tb00410.x","volume":"36","author":"T Andersson","year":"1993","unstructured":"Andersson T, Minors JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolisms. Br J Clin Pharmacol 36:521\u2013530","journal-title":"Br J Clin Pharmacol"},{"key":"189_CR18","first-page":"145","volume":"13","author":"ND Yeomans","year":"1994","unstructured":"Yeomans ND (1994) Omeprazole: short- and long-term safety. Adverse Drug React Toxicol Rev 13:145\u2013156","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"189_CR19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/gut.24.4.270","volume":"24","author":"T Lind","year":"1983","unstructured":"Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 24:270\u2013276","journal-title":"Gut"},{"key":"189_CR20","first-page":"594","volume":"46","author":"SM Morais de","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"189_CR21","first-page":"23","volume":"29","author":"AD Elizabeth","year":"2001","unstructured":"Elizabeth AD, Karen RS, Heng-Keang L, Georgia C, Honglu Z, Simon EB (2001) A method for the simultaneous evaluation of the activities of seven major human drug- metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23\u201329","journal-title":"Drug Metab Dispos"},{"key":"189_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/0049825021000023996","volume":"33","author":"N He","year":"2003","unstructured":"He N, Huang SL, Zhu RH, Tan ZR, Liu J, Zhu B, Zhou HH (2003) Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica 33:211\u2013221","journal-title":"Xenobiotica"},{"key":"189_CR23","first-page":"1195","volume":"262","author":"D Sohn","year":"1992","unstructured":"Sohn D, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T (1992) Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-Mephenytoin 4\u2032-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 262:1195\u20131202","journal-title":"J Pharmacol Exp Ther"},{"key":"189_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0009-9236(95)90192-2","volume":"58","author":"S Yasuda","year":"1995","unstructured":"Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K et al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4\u2032-hydroxylation status. Clin Pharmacol Ther 58:143\u2013154","journal-title":"Clin Pharmacol Ther"},{"key":"189_CR25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.2003.02047.x","volume":"57","author":"N Yasui-Furukori","year":"2004","unstructured":"Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S et al (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57:487\u2013494","journal-title":"Br J Clin Pharmacol"},{"key":"189_CR26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0022-3565(24)37072-7","volume":"283","author":"H Yamazaki","year":"1997","unstructured":"Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434\u2013442","journal-title":"J Pharmacol Exp Ther"},{"key":"189_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/abbi.1994.1259","volume":"311","author":"TH Chang","year":"1994","unstructured":"Chang TH, Gonzalez FJ, Waxman DJ (1994) Evaluation of Triacetyloleandomycin, \u03b1-Nasymphthoflavone and Diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:137\u2013142","journal-title":"Arch Biochem Biophys"},{"key":"189_CR28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF03189869","volume":"16","author":"M Ohtawa","year":"1991","unstructured":"Ohtawa M, Morikawa H, Shimazaki J (1991) Pharmacokinetics and biochemical efficacy after single and multiple oral adiministration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5\u03b1-androst-1-ene-17\u03b2-carboxamide, a new type of specific competitive inhibitor of testosterone 5\u03b1-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 16:15\u201321","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0189-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0189-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0189-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:15:40Z","timestamp":1736536540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0189-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,5]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,10,27]]}},"alternative-id":["189"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0189-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2006,9,5]]}}}